# Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

Source: https://onco.cc/trials/nct07802626/  
OnCo record `nct07802626` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Guardant Reveal in Breast cancer, run by SWOG Cancer Research Network, not yet recruiting.

## Summary

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing is a phase 3 interventional study registered as NCT07802626 by SWOG Cancer Research Network, with 1084 participants planned, started 2026-10-30 and due to reach its primary completion in 2034-10-30. Interventions recorded: NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib, NSAI + CDK4/6i, Guardant Reveal. Conditions recorded: HR Positive/HER-2 Negative Breast Cancer.

Linked to the drug Guardant Reveal because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07802626
- Phase: 3
- Setting: MONITOR (Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, Her2-negative Metastatic Breast Cancer)
- Sponsor: SWOG Cancer Research Network
- Enrolled: 1084

## Sources

- ClinicalTrials.gov NCT07802626: https://clinicaltrials.gov/study/NCT07802626

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Guardant Reveal](https://onco.cc/drugs/guardant-reveal/)

---
JSON: https://onco.cc/api/v1/entities/nct07802626.json